Retail prices for 260 widely used brand-name prescription drugs last year increased by an average 2.9%, more than twice the general rate of inflation, according to a report released yesterday by AARP’s Public Policy Institute.
 
“Increases in the retail price of brand name prescription drugs have a corresponding impact on the cost of therapy for the individual and for all other payers,” the authors note. “In 2020, the average cost of therapy for a brand name prescription drug, based on the market basket in this study, was $6,600 per year.”
 
A second AARP PPI analysis found that Medicare Part D spent nearly $40 billion more on 50 top brand-name drugs between 2015 and 2019 because drug price increases exceeded inflation.

 

Related News Articles

Headline
A new AHIP report makes baseless claims that hospitals drive up specialty drug costs when in fact insurance companies drive up profits by steering patients to…
Blog
A new AHIP “report” suggests that hospitals are significantly marking up the costs of drugs to the detriment of patients. They make baseless claims that…
Headline
About 84% of hospitals had posted a machine-readable file containing rate information by the end of first-quarter 2023, up from 65% the previous quarter,…
Headline
The Medicare Payment Advisory Commission today voted to recommend Congress adopt additional site-neutral payment policies for certain outpatient services;…
Headline
The Centers for Medicare & Medicaid Services this week released for comment initial guidance implementing a program for Medicare to negotiate prices…
Headline
This April through June under the Inflation Reduction Act, Medicare will reduce the coinsurance amount for 27 Part B prescription drugs from 20% to somewhere…